News & Insights

Gunderson Dettmer co-sponsored the Longwood Healthcare Leaders Boston CEO Summit 2025, a two-day, invitation-only conference that convenes approximately 250 biopharma CEOs, R&D executives, government officials, life science investors, and leading academics for off-the-record discussions

Emerald AI announces its oversubscribed $150 million Series A financing at a valuation of $1.05 billion. 

Amplitude Therapeutics, a biotechnology company developing trans-amplifying RNA (taRNA) medicines and vaccines, announces its strategic research collaboration and licensing agreement with Eli Lilly and Company ("Lilly").

Blue Energy announces its $380 million financing led by VXI Capital with significant backing from Engine Ventures and participation from other existing investors, including At One Ventures and Tamarack Global.

Gunderson Dettmer has elected nine new partners effective January 1, 2026, continuing to serve clients throughout the innovation economy

LMG Life Sciences recognizes Gunderson Dettmer with Impact Deal of the Year and names Boston associate Joel Diamond the US Rising Star—Financial and Corporate in its 2025 Life Sciences Americas Awards

Best Lawyers recognizes 38 Gunderson Dettmer attorneys across both the 2026 editions of The Best Lawyers in America list and Best Lawyers: Ones to Watch in America, continuing the legacy of celebrating exceptional legal professionals who have distinguished themselves through insight, expertise, and commitment to excellence